An optimal METRIC for imaging in small bowel Crohn's disease

Isabelle De Kock,Louke Delrue,Pieter Hindryckx

doi:10.1016/s2468-1253(18)30197-3

Isabelle De Kock, Louke Delrue + Show 1 more

Open Access

https://doi.org/10.1016/s2468-1253(18)30197-3

Copy DOI

Abstract

An optimal METRIC for imaging in small bowel Crohn's disease

Highlights

10 Chey WD, Camilleri M, Chang L, et al A randomized placebo-controlled phase iib trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation
Cross-sectional imaging is helpful in the follow-up of patients with small bowel disease, in whom endoscopy is less feasible or is not possible
The study included 147 patients with chronic hepatitis C virus (HCV) infection: 146 had previously had treatment failure with a regimen containing an NS5A inhibitor, and 89% had baseline NS3 or NS5A resistance-associated substitutions. 97% of patients with HCV genotype 1a infection achieved sustained virological response (SVR) 12 weeks after completion of treatment (SVR12), as did all patients with other genotype 1 and genotype 6 infection. 97% of patients with baseline resistance-associated substitutions achieved SVR12, as did all patients without resistance-associated substitutions

Summary

Introduction

10 Chey WD, Camilleri M, Chang L, et al A randomized placebo-controlled phase iib trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Management in Crohn’s disease has evolved beyond the control of clinical symptoms towards a treatto-target strategy, which involves monitoring of therapeutic response through objective interval assessments to avoid long-term complications.[1] In this regard, cross-sectional imaging is helpful in the follow-up of patients with small bowel disease, in whom endoscopy is less feasible or is not possible.

Results

Conclusion